Amgen Shares Soar to New Highs on Strong Q2 Earnings

Amgen's stock price has climbed to new highs in August 2026 after a robust second-quarter earnings report. The biotech company reported Q2 revenue of $10,054 million and net income of $2,375 million, with EPS rising to $6.29.

The strong performance is attributed to the company's diversified portfolio and pipeline prospects. Analysts have responded by increasing their price targets, with one broker revising its target to $457 from $427.

Amgen's shares are currently trading at around $440 on the Nasdaq, representing a 3.3 percent increase over the recent closing price. The stock has advanced 35 percent year-to-date, outperforming some of its peers in the healthcare sector.